Cellyan Biotechnology Co., Ltd income statement HKPD
In fiscal 2025, which ended Mar 31, 2025, Cellyan Biotechnology Co., Ltd reported revenue of $20.3 million. It recorded a net loss of $27,056. The operating loss came to $2.3 million, an operating margin of -11.2%. Diluted earnings per share were -$0.00.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Mar 31, 2025
|
|---|---|
| Revenue |
20
|
| Cost of revenue |
18
|
| Gross profit |
2
|
| Selling, general and administrative |
2
|
| Operating income |
-2
|
| Pretax income |
0
|
| Income tax |
0
|
| Net income |
-0
|
| Basic EPS |
-0.00
|
| Diluted EPS |
-0.00
|
| Weighted average shares, basic |
10
|
| Weighted average shares, diluted |
10
|
| Other measures | |
| Depreciation and amortization |
0
|
| EBITDA |
-2
|
| Interest coverage |
-23.39x
|
| Margins | |
| Gross margin |
11.89%
|
| Operating margin |
-11.25%
|
| Pretax margin |
0.18%
|
| Profit margin |
-0.13%
|
| EBITDA margin |
-10.92%
|
| Effective tax rate |
174.92%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
- Listed as
- HKPD (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Kowloon
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2007702
- Former names
- Hong Kong Pharma Digital Technology Holdings Ltd (until Dec 17, 2025)
Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Mckesson Corp MCK
- Cencora, Inc. COR
- Cardinal Health Inc CAH
- Herbalife Ltd. HLF
- Nu Skin Enterprises, Inc. NUS
- EnerSyn Global Inc. ESYN
- Cosmos Health Inc. COSM
- DataMeds AI, Inc. MEDS
All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.